| Autor: |
Sørensen JB; Department of Oncology, Finsen Institute, Copenhagen, Denmark., Bach F, Dombernowsky P, Vibe-Petersen J, Hansen HH |
| Jazyk: |
angličtina |
| Zdroj: |
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 1990 Jul; Vol. 1 (4), pp. 299-300. |
| DOI: |
10.1093/oxfordjournals.annonc.a057753 |
| Abstrakt: |
TCNU, a new water soluble nitrosourea, has in preclinical studies shown higher activity when given as divided doses compared with one day single treatment. Accordingly, 38 consecutive patients with non-resectable adenocarcinoma of the lung received TCNU 40 mg/m2 p.o. daily for three days every 4 weeks. The response rate among 37 evaluable patients was 14%, median response duration was 17 weeks (range 5-57+ weeks) and median survival 22 weeks (range 3-96+ weeks). Hematologic toxicity was pronounced, especially thrombocytopenia, and 57% of the patients had WHO grade 3 or 4 WBC or platelet count. Overall, dose reduction or delay of treatment due to hematologic toxicity was necessary in 66% of the patients. This, together with the limited activity, renders TCNU in the present dose and schedule unsuitable for further investigations in this disease entity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
